Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a ... Read More
Boehringer Ingelheim and Zealand Pharma have announced further data showcasing the superior efficacy of survodutide (BI 456906) compared to placebo in individuals with overweight or ... Read More